Does adding ribociclib to adjuvant endocrine therapy in early breast cancer reduce recurrence?

An exploratory evaluation published in JAMA Oncology examined the long-lasting efficiency and safety and security of adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with hormone receptor– positive, HER2-negative early breast cancer cells.

#breastcancer #oncology